Detail akcie Hoth Therap Rg online

Business Summary: Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Hoth Therapeutics Inc revenues was not reported. Net loss increased 64% to $9.8M. Higher net loss reflects Pharmaceutical segment loss increase from $3.8M to $9.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.04 to -$0.74.